Oshadi Drug Administration
9
0
0
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 9 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
Efficacy Safety and Tolerability of Multiple Doses of Oshadi Icp (Oshadi Oral Insulin) in Patients With Type 1 Diabetes Mellitus - Phase II Clinical Study
Role: lead
Oshadi D and Oshadi R in Combination With Docetaxel, as 2nd Line Therapy for Metastatic Non Small Cell Lung Cancer
Role: lead
Safety and Efficacy of Oshadi D and Oshadi R in Basal Cell Carcinoma Patients Prior to Tumor Excision a Phase 2 Study
Role: lead
Safety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma Treatment
Role: lead
Oshadi D & Oshadi R Combined With Salvage Chemotherapy for Relapsed Acute Myeloid Leukemia or Lymphoid Leukemia Patients
Role: lead
Safety and Tolerability of Oshadi Icp In Patients With Type 1 Diabetes Mellitus - Phase Ib Clinical Study
Role: lead
Evaluation of the Influence of Food Regimen on Oshadi D Absorption
Role: lead
Evaluation of the Safety and Efficacy of Oshadi D and Oshadi R for Cancer Treatment
Role: lead
Safety and Efficacy of Single Administration of Oshadi Oral Insulin in Type I Diabetes Patients
Role: lead
All 9 trials loaded